Latest rheumatoid arthritis Stories

THE WOODLANDS, Texas, Aug. 16, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101. The Phase 1 study of LX2931, an inhibitor of sphingosine-1-phosphate lyase, was a dose-ranging study to explore higher doses of LX2931 in patients with rheumatoid arthritis. The study involved 10 patients with...

Researcher finds autoimmune response contributes to inflammation in the artery wall Most people probably know that heart disease remains the nation's No. 1 killer. But what many may be surprised to learn is that cholesterol has a major accomplice in causing dangerous arterial plaque buildup that can trigger a heart attack. The culprit? Inflammatory cells produced by the immune system. A number of research studies have demonstrated inflammation's role in fueling plaque buildup, also...

Muscle atrophy a major problem with arthritis, could be treated with regenerative medicine, according to A.J. Farshchian MD from the Center for Regenerative Medicine. (PRWEB) August 12, 2012 Muscle atrophy a major problem with arthritis, could be treated with regenerative medicine, according to A.J. Farshchian MD from the Center for Regenerative Medicine. Muscle atrophy also known as Muscle wasting Is common in arthritis and is usually due to loss of muscle tissue which could be caused by...

Might be potential trigger and/or help sustain inflammation suggest researchers Gum disease is not only four times as common among patients with the autoimmune disease rheumatoid arthritis as it is among their healthy peers, but it also tends to be more severe, indicates a small study published online in the Annals of the Rheumatic Diseases. The researchers base their findings on 91 adults with confirmed rheumatoid arthritis (RA) and a comparison group of 93 healthy people, matched for...

Study compares overall mortality in TNF inhibitors: Humira, Enbrel, and Remicade New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Sweden—the first to compare mortality rates among patients treated with individual TNF inhibitors—is now...

NEW YORK, Aug. 7, 2012 /PRNewswire/ -- Sjogren's Syndrome is a chronic autoimmune disease in which a person's white blood cells attack their moisture-producing glands. It is estimated that this disease affects as many as 4 million Americans, most of which are women. Those living with the disease are afflicted with dryness in various parts of their body and typically are also pained by other autoimmune disorders, such as rheumatoid arthritis or systemic lupus erythematosus....

DEERFIELD, Ill., July 26, 2012 /PRNewswire/ -- Horizon Pharma, Inc., (NASDAQ: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS(®) (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD) (see full prescribing information at...

NEW YORK, July 25, 2012 /PRNewswire/ -- Pharmspective, LLC, the specialty therapeutics market research firm, announced today the release of its two newest syndicated market research reports, Rheumatoid Arthritis Pipeline Perspectives - http://bit.ly/MjeXFo and Psoriasis Pipeline Perspectives - http://bit.ly/PKpqK0 These new Pharmspective reports coincide with a number of key milestones in Rheumatoid Arthritis (RA) & Psoriasis product development: Tofacitinib 2nd line...

MELBOURNE, Australia, July 23, 2012 /PRNewswire/ -- Key Points: * Intravenous injection of Mesenchymal Precursor Cells (MPCs) resulted in selective migration to inflamed joints and lymph nodes in a sheep model of Rheumatoid Arthritis (RA) * A single intravenous injection of allogeneic, or "off-the-shelf", MPCs significantly reduced synovial tissue levels of TNF-alpha, IL-6, and IL-17, and reduced mononuclear cell infiltration * Reduced cytokine and inflammatory cell levels were...

RA patients emphasize pain, physicians stress swollen joints to explain change in disease Researchers from Austria have determined that patients with rheumatoid arthritis (RA) and their doctors differ on perception of RA disease activity. The study now available in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR) and published by Wiley, reports that RA patients cite joint pain as the reason for their perception of a change in their disease activity....